The business must take decisive steps to strengthen its finances and win back investor trust. It's crucial to understand that things are still changing and that new developments could impact Byju's ...
Third quarter results highlight strong operational performance across key value drivers: YUPELRI® (revefenacin) net sales of $62.2 million, recognized by Viatris ...